Optimal variants of treatment of stage I endometrial carcinoma and its choice

• Published in: European journal of gynaecological oncology Vol. 14; no. 2; p. 154
• Main Author: Charkviani, T L
• Format: Journal Article
• Language: English
• Published: Italy 1993
• Subjects: Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - therapy; Antineoplastic Agents - therapeutic use; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial Neoplasms - mortality; Endometrial Neoplasms - pathology; Endometrial Neoplasms - therapy; Female; Humans; Hydroxyprogesterones - therapeutic use; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasms, Hormone-Dependent - mortality; Neoplasms, Hormone-Dependent - pathology; Neoplasms, Hormone-Dependent - therapy; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome
• ISSN: 0392-2936

2195 patients affected by endometrial carcinoma were treated at the Tbilisi and the St. Petersburg Oncological Institutes from 1968 to 1987. The incidence of different stages was respectively: I 78.8%; II 11.6%; III 9.0%; IV 0.4%. Adenocarcinoma was the histotype more frequently observed and the grade of differentiation was respectively: G1 39.3%; G2 51.3%; G3 9.4%. The incidence of lymphnodal invasion was equal to 6.2% in I Stage, 12.2% in II Stage and 37.8% in III Stage. In Stage I surgery was the treatment of choice in all cases and in the 70.5% of cases additional treatments were added: in G1, G2 grade endometrial cancer additional hormone therapy, remote irradiation and postoperative hormone therapy were used, whereas in G3 tumours intracavitary irradiation was frequently added in the St. Petersburg Institute. The 5 year survival rate of patients at Stage I was equal to 70.9% in retrospective analysis (1968-1982) and 84.6% in patients followed prospectively (1983-1987).